54 results about "Mycobacterial disease" patented technology

Mycobacterial proteins from culture filtrate or cytosol are disclosed as being useful B cell antigens for early diagnosis of mycobacterial disease, particularly in humans. These proteins include four that had not previously been recognized as B cell antigens (LppZ protein encoded by Mtb gene Rv3006; SodC protein encoded by Mtb gene Rv0432; BfrB protein encoded by Mtb gene Rv3841 and TrxC protein encoded byMtb gene Rv3914). Antigenic compositions include these proteins and/or peptide fragments thereof, in various combinations with each other or with one or more of a set of 10 additional Mtb proteins known to be antigens (in paricular early antigens. Methods and kits for using these antigenic composition for early diagnosis of mycobacterial infection and disease are also disclosed.

The present invention relates to a compound of formula (I)

or a pharmaceutically acceptable salt thereof wherein X and R are as defined herein. The compounds of formula (I) are useful as gyrase and/or topoisomerase IV inhibitors for treating bacterial infections. The compounds of formula (I) either possess a broad range of anti-bacterial activity and advantageous toxicological properties or are prodrugs of compounds having said activity.

A number of protein and glycoprotein antigens secreted by Mycobacterium tuberculosis (Mtb) have been identified as “early” Mtb antigens on the basis early antibodies present in subjects infected with Mtb prior to the development of detectable clinical disease. Epitope-bearing peptide fragments of these early Mtb antigens, in particular of an 88 kDa secreted protein, GlcB (SEQ ID NO:106) and of Mtb antigen MPT51 (SEQ ID NO:107) have been identified. These peptides, variants thereof, peptide multimers thereof that include two or more repeats of one or more of the peptides, and fusion polypeptides that include early Mtb antigenic proteins, peptides or both, are useful in immunoassay methods for early, rapid detection of TB in a subject. Preferred immunoassays detect the antibodies in the subject's urine. Also provided are antigenic compositions, kits and methods to useful for detecting an early Mtb antibodies. The antigenic proteins and peptides are also used in vaccine compositions.

The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or the general Formula (Ib)

the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. The claimed compounds are useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as Mycobacterium tuberculosis, M. bovis, M. avium and M. marinum. In particular, compounds are claimed in which, independently from each other, R¹ is bromo, p=1, R² is alkyloxy, R³ is optionally substituted naphthyl or phenyl, q=1, R⁴ and R⁵ each independently are hydrogen, methyl or ethyl, R⁶ is hydrogen, r is equal to 0 or 1 and R⁷ is hydrogen. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of mycobacterial diseases and a process for preparing the claimed compounds.

The invention relates to a disinfectant, in particular to a preparation and application of a compound disinfectant containing various disinfection components, and the compound disinfectant comprises the following components by weight percent: 0.01%-5% of guanidine compound, 0.01%-10% of quaternary ammonium salt compound, 0.01%-2% of trilon B, 0.01%-2% of 2-bromo-2-nitro-1,3-propanediol, 0.01%-10% of monohydric alcohol, 0%-30% of dihydric alcohol, 0%-30% of polyhydric alcohol and the balance of water. The invention further provides the application of the compound disinfectant composition, the compound disinfectant composition can be applied in disinfection of object surfaces, air-conditioning systems, environments and air in the field of public health, the field of food processing and the filed of medical sanitation through a multifunctional atomizing machine for effectively preventing and killing vegetative forms of bacteria, mycobacteria, viruses, fungi and spores thereof, and the like, can be applied in the disinfection of the air in automobiles, the object surfaces and the air-conditioning systems through the multifunctional atomizing machine for effectively preventing and killing the vegetative forms of the bacteria, the mycobacteria, the viruses and the like, can be applied in the disinfection of the air in train carriages, cabins and the automobiles and the disinfection of objects and the environments through the multifunctional atomizing machine for effectively preventing and killing the vegetative forms of the bacteria, the mycobacteria, the viruses and the like, can be further applied in the disinfection of the environments, indoor spaces and the object surfaces in the field of livestock and poultry breeding through the multifunctional atomizing machine for effectively preventing and killing the vegetative forms of the bacteria, the mycobacteria, the viruses, the fungi and the spores thereof, and the like.

The present invention relates to the use of a substituted quinoline derivative for the preparation of a medicament for the treatment of an infection with a drug resistant Mycobacterium strain wherein the substituted quinoline derivative is a compound according to Formula (Ia) or Formula (Ib) the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the above compounds and one or more other antimycobacterial agents.

The present invention relates to vesicular formulations containing a prodrug, characterized for comprising the combination of a prodrug of weak organic acids having the following general formula: R₁COOH (I) or R₁SO₂H (II) wherein R₁ is preferably selected from the group containing a benzenic, pyridinic, pyrazinic or pyrimidinic aromatic ring, or a linear chain substituted or unsubstituted, saturated or unsaturated, such as benzoic, benzenesulphinic, cinnamic, salicylic, pyrazinoic, nicotinic, carboxylic pyridazine and carboxylic pyrimidine, caproic, caprylic, capric, lauric, myristic, palmitic and estearic acids; with a liposomal or micellar carrier, which protects the prodrug from plasma degradation. The invention further relates to the process of preparation of liposomal formulations, novel prodrugs and pharmaceutical compositions intended for use in the treatment of tuberculosis and other mycobacterioses.

Novel compounds belonging to the class of oxazolidinones possessing potent antimycobacterial properties especially useful in the treatment of acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium-intracellular complex, M. fortuitum and M. kansai. The compound and its pharmaceutically acceptable salts thereof act as antibacterial agents. Also disclosed is a method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial conditions such as Mycobacterium tuberculosis, drug resistant Mycobacterium tuberculosis, Mycobacterium avium-intracellular complex, M. fortuitum and M. kansai, comprising administering an antimycobacterially effective amount of the said compound and/or pharmaceutically acceptable salts thereof. There is also disclosed a process for the manufacture of the said compound or its pharmaceutically acceptable salts.

Methods and compositions for the detection and diagnosis of infectious diseases are provided. In particular, efficient and sensitive methods and compositions for the detection of active mycobacterial disease are provided for distinguishing between individuals having active disease, and individuals who have been immunologically exposed, such as those infected with a mycobacterium but are without active disease, or those who have been vaccinated with BCG. The methods comprise topical application of antigen compositions for transdermal delivery.

The present invention relates to pharmaceutical compositions of calanolides, their derivatives and analogues, and process for producing the same having enhanced solubility and bioavailability for oral or parenteral administration. The invention further provides for a method of using the disclosed compositions for the treatment and prevention of retroviral diseases such as human immunodeficiency, specifically HTV-1 and mycobacterial diseases especially tuberculosis infections in mammals, particularly humans.

The invention provides a kit for identifying nucleic acid of mycobacterium pathogeny through multiple PCR (polymerase chain reaction). The kit comprises primer composition as follows: 5'-acggtgggtactaggtgtgggtttc-3', 5'-tctgcgattagcgactaagacttca-3', 5'-gcgttgaccgagatggattat-3', 5'-gctcatctcacccagttggc-3', 5'-ttccgaatcccttgtga-3', 5'-ggagagcgccgttgta-3' or 5'-agtcgccgtggcttctctttta-3'. The kit has high sensitivity and high specificity, is simple to operate and can realize rapid and large-flux detection for virulent and avirulent mycobacterium.

The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or Formula (Ib):

the pharmaceutically acceptable acid or base addition salts thereof, the quaternary amines thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. The claimed compounds are useful for the treatment of a bacterial disease including a mycobacterial disease, particularly those diseases caused by pathogenic mycobacteria such as Mycobacterium tuberculosis, M. bovis, M. avium and M. marinum. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of bacterial diseases and a process for preparing the claimed compounds.

The present invention provides a solid carrier capable of easily and accurately evaluating the activity of mycobacteriosis or the presence or absence of mycobacterial infection. The solid carrier for detecting mycobacteriosis or mycobacterial infection includes at least one probe including a polynucleotide consisting of a base sequence complementary to all or a part of a base sequence having 85% or more identity with respect to a base sequence set forth in SEQ ID NO: 1, which is immobilized on a surface thereof.

The present invention provides novel markers of treatment response in a subject infected with Mycobacterium, which allow for quantifying treatment impact on the physiologic state of the Mycobacterium.

A mycobacterial disease microarray detection chip includes a plurality of probes immobilized on a matrix, wherein each of the probe is selected from the group of deoxyribonucleotide sequences depicted in the SEQ ID NOs. 1 to 66. Since these probes are formed with deoxyribonucleotide sequences specific to mycobacterial disease, they can be used to detect whether the patient has contracted mycobacterial disease and the mycobacterial disease pathogen infected the patient has drug resistance.

The present invention relates to mycobacterial lipoarabinomannan cap-specific mannosyl transferases and nucleic acid encoding such transferases. The invention further relates to Mycobacteria in which the lipoarabinomannan cap-specific mannosyl transferases have been inactivated and that therefore express mannose cap-deficient lipoarabinomannan. Such Mycobacteria with mannose cap-deficient lipoarabinomannan may be used as more effective vaccines against mycobacterial diseases as they lack the immunosuppressive action of the mannose cap.

The present invention relates to methods for treating a subject suffering from infection with Mycobacteria, such as M. leprae or M. tuberculosis comprising administering to the subject a composition comprising a bactericidal/permeability-inducing (BPI) protein product alone or in combination with administration of an anti-Mycobacterial antibiotic.